Home Search
ardx - search results
If you're not happy with the results, please do another search
Ardelyx (ARDX) Reports First Quarter 2024 Showing $204 Million in Cash!
When we added Ardelyx (ARDX) to the Watch List in November of 2022, the market cap near $80 million. Now it's approaching $2...
Ardelyx (ARDX), Raymond James up Price Target, Citigroup Joins the Party.
Wall Street Cozy's up to Ardelyx After New Guidance.
On January 8th, Mike Raab, President and Chief Executive Officer stated, "We consistently grew sales of...
Ardelyx (ARDX) Firmly Above Resistance.
Were not traders and we don't do technical analysis, but we could see this coming from a mile away. Next stop $9.00 and then...
Ardelyx (ARDX) $3.40, Receives FDA Approval.
BooYah, Ardelyx shoots and we score (again) last week..but wait, there's more!
It trades down post-approval as short-term impatient traders expecting a multi-dollar 'pop'...
Is Ardelyx (ARDX) $4.00 Ready to Break Out?
We're up 160% ($579 million) in Ardelyx since adding it to the Watch List about ten months ago in November, but we feel the...
Ardelyx (ARDX) Resubmits New Drug Application to FDA.
WALTHAM, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize...
And we Have Another Triple! Ardelyx (ARDX) Touches $5.00, up 333%.
LIVE QUOTE
Ardelyx Enters the Danger Zone* With Tenapanor.
The company produced favorable (albeit very technical) information (data) at the National Kidney Foundation 2023 Spring Clinical...
Booya. We’re up 143% With Ardelyx (ARDX) in Three Months – and That Ain’t...
Ardelyx Adds 16% to $3.82 as Wedbush Upgrades After Q4 Earnings.
Ardelyx ( NASDAQ: ARDX ) gained 35% Friday after the biotech reported better-than-expected financials...
He Shoots And He Scores. Ardelyx (ARDX) Gains 78%. Happy New Year!
Ah yes, and Gains Come to the Patient, as the FDA Moves the Ardelyx Ball Further Along.
Despite the 78% gain since November 17th, the...
Ardelyx (ARDX). Don’t be Nervous, It’s Just Money.
The Higher it Goes, The More Nervous we Get.
LIVE QUOTE
Not much to report here, other then there could be news any day, any week....
Latest article
Jeffrey Gundlach: Reckoning is Coming.
Jeffrey Edward Gundlach is a businessman, fund manager, and philanthropist. He is the founder of DoubleLine Capital, an investment firm.
On 11 November 2020, Gundlach remarked in an interview with...
Who’s the Next Eric Sprott?
Eric Sprott, on Who is the Next Eric Sprott!
To say Eric Sprott has left a legendary mark on the world of mining investment would...
Perpetua (PPTA) Raises $300 Million.
Not a bad day in Idaho. $300 million banked! We look at the dip as a buying opportunity, as does John Paulson & Co.,...
